Iovance Biotherapeutics, Inc. (0JDK.L)
USD 3.4
(3.07%)
USD 3.4
(3.07%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 450.99 Million USD | 19.39% |
| 2022 | 377.74 Million USD | 14.91% |
| 2021 | 328.72 Million USD | 29.81% |
| 2020 | 253.22 Million USD | 27.41% |
| 2019 | 198.74 Million USD | 56.12% |
| 2018 | 127.3 Million USD | 38.48% |
| 2017 | 91.92 Million USD | 74.56% |
| 2016 | 52.66 Million USD | 96.05% |
| 2015 | 26.86 Million USD | 123.08% |
| 2014 | 12.04 Million USD | -51.71% |
| 2013 | 24.93 Million USD | 2709.27% |
| 2012 | 887.66 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 105.9 Million USD | -1.63% |
| 2024 Q2 | 101.65 Million USD | -4.01% |
| 2023 Q2 | 102.36 Million USD | -2.66% |
| 2023 Q3 | 108.62 Million USD | 6.11% |
| 2023 Q4 | 107.65 Million USD | -0.89% |
| 2023 Q1 | 105.15 Million USD | 3.78% |
| 2023 FY | 428.62 Million USD | 13.47% |
| 2022 Q4 | 101.32 Million USD | 6.45% |
| 2022 Q3 | 95.19 Million USD | 0.7% |
| 2022 Q2 | 94.53 Million USD | 8.99% |
| 2022 Q1 | 86.73 Million USD | -8.59% |
| 2022 FY | 377.74 Million USD | 14.91% |
| 2021 Q4 | 94.88 Million USD | 18.61% |
| 2021 Q1 | 72.91 Million USD | 4.1% |
| 2021 Q2 | 80.93 Million USD | 11.01% |
| 2021 FY | 328.72 Million USD | 29.81% |
| 2021 Q3 | 79.99 Million USD | -1.17% |
| 2020 Q1 | 70.76 Million USD | 9.33% |
| 2020 Q3 | 58.96 Million USD | -7.33% |
| 2020 FY | 253.22 Million USD | 27.41% |
| 2020 Q4 | 70.04 Million USD | 18.78% |
| 2020 Q2 | 63.62 Million USD | -10.08% |
| 2019 Q2 | 50.16 Million USD | 25.46% |
| 2019 Q1 | 39.98 Million USD | 18.97% |
| 2019 FY | 198.74 Million USD | 56.12% |
| 2019 Q4 | 64.72 Million USD | 25.41% |
| 2019 Q3 | 51.61 Million USD | 2.88% |
| 2018 Q1 | 26.87 Million USD | 3.02% |
| 2018 Q3 | 35.05 Million USD | 11.73% |
| 2018 Q2 | 31.37 Million USD | 16.75% |
| 2018 FY | 127.3 Million USD | 38.48% |
| 2018 Q4 | 33.61 Million USD | -4.13% |
| 2017 Q1 | 20.88 Million USD | 31.15% |
| 2017 Q3 | 22.34 Million USD | -5.25% |
| 2017 Q4 | 26.09 Million USD | 16.77% |
| 2017 FY | 91.92 Million USD | 74.56% |
| 2017 Q2 | 23.58 Million USD | 12.93% |
| 2016 Q4 | 15.92 Million USD | -16.11% |
| 2016 Q1 | 7.01 Million USD | -17.33% |
| 2016 Q3 | 18.97 Million USD | 61.84% |
| 2016 FY | 52.66 Million USD | 96.05% |
| 2016 Q2 | 11.72 Million USD | 67.29% |
| 2015 Q4 | 8.47 Million USD | 10.94% |
| 2015 FY | 26.86 Million USD | 123.08% |
| 2015 Q3 | 7.64 Million USD | 18.68% |
| 2015 Q2 | 6.44 Million USD | 21.56% |
| 2015 Q1 | 5.29 Million USD | 8.83% |
| 2014 Q4 | 4.86 Million USD | 73.67% |
| 2014 FY | 12.04 Million USD | -51.71% |
| 2014 Q1 | 2.25 Million USD | -80.35% |
| 2014 Q2 | 2.11 Million USD | -6.61% |
| 2014 Q3 | 2.8 Million USD | 32.83% |
| 2013 Q1 | 704.91 Thousand USD | -86.07% |
| 2013 Q4 | 11.49 Million USD | 22.2% |
| 2013 Q2 | 3.32 Million USD | 371.71% |
| 2013 Q3 | 9.4 Million USD | 182.97% |
| 2013 FY | 24.93 Million USD | 2709.27% |
| 2012 Q4 | 5.06 Million USD | 0.0% |
| 2012 FY | 887.66 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 95.602% |
| Dynavax Technologies Corporation | 219.14 Million USD | -105.797% |
| Illumina, Inc. | 3.81 Billion USD | 88.172% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 78.032% |
| Biogen Inc. | 5.2 Billion USD | 91.335% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 58.601% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 66.859% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 14.748% |
| Waters Corporation | 943.51 Million USD | 52.201% |
| Perrigo Company plc | 1.52 Billion USD | 70.494% |
| uniQure N.V. | 285.08 Million USD | -58.195% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -10.32% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -5.458% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -63.585% |
| bluebird bio, Inc. | 240.23 Million USD | -87.732% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -216.569% |
| Imunon, Inc. | 21.03 Million USD | -2044.478% |
| Myriad Genetics, Inc. | 600.1 Million USD | 24.847% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 71.751% |
| Nektar Therapeutics | 190.9 Million USD | -136.242% |
| Editas Medicine, Inc. | 247.3 Million USD | -82.364% |
| Verastem, Inc. | 92.08 Million USD | -389.763% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 98.889% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -3142.305% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -273.781% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -909.678% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 74.174% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -97.216% |
| Evolus, Inc. | 189.75 Million USD | -137.666% |
| Adicet Bio, Inc. | 152.03 Million USD | -196.632% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -3614.628% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 83.981% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -65.869% |
| FibroGen, Inc. | 398.11 Million USD | -13.283% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 78.676% |
| OPKO Health, Inc. | 574.68 Million USD | 21.524% |
| Homology Medicines, Inc. | 9.87 Million USD | -4467.018% |
| Geron Corporation | 70.44 Million USD | -540.242% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 74.946% |
| Exelixis, Inc. | 1.58 Billion USD | 71.578% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -347.294% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -708.869% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 18.234% |
| Zoetis Inc. | 2.76 Billion USD | 83.689% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 5.325% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -829.844% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 90.555% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -1051.873% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 42.15% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -22.349% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -50.674% |
| Blueprint Medicines Corporation | 722.86 Million USD | 37.61% |
| Insmed Incorporated | 949.26 Million USD | 52.49% |
| TG Therapeutics, Inc. | 198.47 Million USD | -127.229% |
| Incyte Corporation | 1.19 Billion USD | 62.117% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 56.801% |